Skip to main content
. 2024 Dec 19;28:0098. doi: 10.34133/bmr.0098

Fig. 6.

Fig. 6.

Safety evaluation of PMELNVs in vivo. (A) Skin condition before dosing every other day. (B and D) H&E-stained sections of major organs and skin tissue. (C) Changes in body weight. (E to G) Levels of RBC, WBC, and PLT. (H to L) Blood biochemical levels of ALT, AST, BUN, CR, and UA.